Assessment of anatomic and physiological severity of single-vessel coronary artery lesions by dipyridamole echocardiography. Comparison with positron emission tomography and quantitative arteriography. 1994

E Picano, and O Parodi, and F Lattanzi, and G Sambuceti, and M J Andrade, and P Marzullo, and A Giorgetti, and P Salvadori, and M Marzilli, and A Distante
CNR, Institute of Clinical Physiology, Pisa, Italy.

BACKGROUND The aim of this study was to compare the results of dipyridamole-echocardiography test (DET: two-dimensional echo monitoring during dipyridamole infusion up to 0.84 mg/kg over a period of 10 minutes) with both anatomic and physiological parameters of coronary artery disease severity, assessed by computer-assisted quantitative coronary arteriography, and regional coronary flow reserve, measured by [13N]ammonia (13NH3) and dynamic positron emission tomography (PET), respectively. RESULTS We studied 31 patients with a history of chest pain and neither previous myocardial infarction nor resting wall motion abnormalities. Eighteen patients had single-vessel disease (> 50% stenosis of one major coronary vessel), and 13 had normal coronary arteries. The criterion for DET positivity was the appearance of a new transient regional wall motion abnormality. In patients with a positive DET, two parameters were evaluated: the dipyridamole time (ie, the time from the beginning of drug infusion to the development of obvious dyssynergy) and the wall motion score index (WMSI, a semiquantitative integrated estimation of extent and severity of the stress-induced dyssynergy). WMSI was derived by summation of individual segment scores divided by the number of segments interpreted. Quantification of regional myocardial blood flow was obtained by PET measurements of 13NH3 arterial input function and left ventricular myocardial tissue concentration both at control and after dipyridamole (0.56 mg/kg over 4 minutes). Maximal regional blood flow after dipyridamole in the region supplied by the stenotic vessel was significantly lower in the 11 patients with coronary artery disease and positive DET than in the 7 patients with coronary artery disease and negative DET (1.08 +/- 0.33 versus 1.98 +/- 0.37 mL.min-1.g-1, P < .01). In patients with a positive DET, regional coronary flow reserve correlated well with dipyridamole time (r = .87, P < .01) but not with peak WMSI (r = .25, P = NS). Patients with dipyridamole-induced akinesia or dyskinesia (n = 6) had a greater reduction in regional coronary flow reserve than did those showing hypokinesia (n = 5): 1.38 +/- 0.51 versus 2.17 +/- 0.42, P < .05. Percent area reduction was more severe in patients with DET positivity than in those with DET negativity (93.7 +/- 8.7% versus 77 +/- 10.3%, P < .01), and it correlated with regional coronary flow reserve (r = .64, P < .01) and dipyridamole time (r = -.59, P < .01). CONCLUSIONS In patients with single-vessel disease, DET shows an excellent specificity but a limited sensitivity; in these patients, DET positivity is associated with a physiologically important coronary stenosis. Severity of the anatomic stenosis and impairment in regional flow reserve are greater when the dipyridamole-induced dyssynergy appears earlier during the test. Therefore, a stratification of the anatomo-physiological severity of coronary artery disease can be obtained with DET, based mainly on the temporal allocation of the transient dyssynergy.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D003326 Coronary Circulation The circulation of blood through the CORONARY VESSELS of the HEART. Circulation, Coronary
D003327 Coronary Disease An imbalance between myocardial functional requirements and the capacity of the CORONARY VESSELS to supply sufficient blood flow. It is a form of MYOCARDIAL ISCHEMIA (insufficient blood supply to the heart muscle) caused by a decreased capacity of the coronary vessels. Coronary Heart Disease,Coronary Diseases,Coronary Heart Diseases,Disease, Coronary,Disease, Coronary Heart,Diseases, Coronary,Diseases, Coronary Heart,Heart Disease, Coronary,Heart Diseases, Coronary
D004176 Dipyridamole A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752) Antistenocardin,Apo-Dipyridamole,Cerebrovase,Cléridium,Curantil,Curantyl,Dipyramidole,Kurantil,Miosen,Novo-Dipiradol,Persantin,Persantine,Apo Dipyridamole,Novo Dipiradol
D004452 Echocardiography Ultrasonic recording of the size, motion, and composition of the heart and surrounding tissues. The standard approach is transthoracic. Echocardiography, Contrast,Echocardiography, Cross-Sectional,Echocardiography, M-Mode,Echocardiography, Transthoracic,Echocardiography, Two-Dimensional,Transthoracic Echocardiography,2-D Echocardiography,2D Echocardiography,Contrast Echocardiography,Cross-Sectional Echocardiography,Echocardiography, 2-D,Echocardiography, 2D,M-Mode Echocardiography,Two-Dimensional Echocardiography,2 D Echocardiography,Cross Sectional Echocardiography,Echocardiography, 2 D,Echocardiography, Cross Sectional,Echocardiography, M Mode,Echocardiography, Two Dimensional,M Mode Echocardiography,Two Dimensional Echocardiography
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

E Picano, and O Parodi, and F Lattanzi, and G Sambuceti, and M J Andrade, and P Marzullo, and A Giorgetti, and P Salvadori, and M Marzilli, and A Distante
April 1989, Circulation,
E Picano, and O Parodi, and F Lattanzi, and G Sambuceti, and M J Andrade, and P Marzullo, and A Giorgetti, and P Salvadori, and M Marzilli, and A Distante
August 1988, Circulation,
E Picano, and O Parodi, and F Lattanzi, and G Sambuceti, and M J Andrade, and P Marzullo, and A Giorgetti, and P Salvadori, and M Marzilli, and A Distante
June 1991, The American journal of cardiology,
E Picano, and O Parodi, and F Lattanzi, and G Sambuceti, and M J Andrade, and P Marzullo, and A Giorgetti, and P Salvadori, and M Marzilli, and A Distante
June 1989, The American journal of cardiology,
E Picano, and O Parodi, and F Lattanzi, and G Sambuceti, and M J Andrade, and P Marzullo, and A Giorgetti, and P Salvadori, and M Marzilli, and A Distante
May 1988, Journal of the American College of Cardiology,
E Picano, and O Parodi, and F Lattanzi, and G Sambuceti, and M J Andrade, and P Marzullo, and A Giorgetti, and P Salvadori, and M Marzilli, and A Distante
July 1994, American heart journal,
E Picano, and O Parodi, and F Lattanzi, and G Sambuceti, and M J Andrade, and P Marzullo, and A Giorgetti, and P Salvadori, and M Marzilli, and A Distante
February 2003, Clinical cardiology,
E Picano, and O Parodi, and F Lattanzi, and G Sambuceti, and M J Andrade, and P Marzullo, and A Giorgetti, and P Salvadori, and M Marzilli, and A Distante
January 2004, Journal of the American College of Cardiology,
E Picano, and O Parodi, and F Lattanzi, and G Sambuceti, and M J Andrade, and P Marzullo, and A Giorgetti, and P Salvadori, and M Marzilli, and A Distante
September 2023, Archivos de cardiologia de Mexico,
E Picano, and O Parodi, and F Lattanzi, and G Sambuceti, and M J Andrade, and P Marzullo, and A Giorgetti, and P Salvadori, and M Marzilli, and A Distante
April 1995, European heart journal,
Copied contents to your clipboard!